Carlos de Sousa-arkiv - BioStock

Ultimovacs_NIPU_survival

Ultimovacs reaches proof of concept with UV1 cancer vaccine

20 October, 2023

Ultimovacs INITIUM study timeline

Ultimovacs updates INITIUM study timeline

28 April, 2023

Ultimovacs on track for phase II

Ultimovacs on track to phase II readout

24 February, 2023

Uppsala's life science sector continues to grow

Uppsala’s life science sector continues to grow

2 December, 2022

Ultimovacs clinical transition

Ultimovacs poised for major clinical transition

15 November, 2022

Ultimovacs studie fullrekryterad

Ultimovacs’ malignant melanoma study fully recruited

1 July, 2022

Ultimovacs Patent Protection

Ultimovacs protects cancer vaccine technology until 2037

26 April, 2022

Ultimovacs wave of positive momentum

Ultimovacs to ride wave of positive momentum in 2022

22 February, 2022

Ultimovacs sees first patient enrolled in DOVACC trial

Ultimovacs sees first patient enrolled in DOVACC trial

17 December, 2021

Ultimovacs’ UV1 granted orphan drug designation

Ultimovacs’ UV1 granted orphan drug designation

7 December, 2021

12 Page 1 of 2